Alterations in mRNA and protein expression in human peripheral mononuclear blood cells (pmc) of schizophrenia patients treated with fluvoxamine augmentation of antipsychotics: Relationship to clinical symptoms and cognitive function

Trial Profile

Alterations in mRNA and protein expression in human peripheral mononuclear blood cells (pmc) of schizophrenia patients treated with fluvoxamine augmentation of antipsychotics: Relationship to clinical symptoms and cognitive function

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Fluvoxamine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top